title: Development of a novel engineered antibody targeting human CD123.
abstract: Antibody engineering involves a range of custom modifications of immunoglobulins to improve their affinity, valency, and pharmacokinetics, ensuring a better target therapy achievement. A number of therapeutic antibodies have been used for cell surface receptor blockage, interfering with the ligand binding and inhibiting receptor-driven activation of cells. Here we describe the construction and characterization of a recombinant bivalent single-chain Fv (biscFv) that targets CD123. On conversion of anti-CD123 scFv to biscFv format, the recognition of the cognate ligand is not altered. Moreover, the increased overall efficacy of the anti-CD123 biscFv in binding and inhibition of CD123/IL-3 (interleukin-3) interactions in TF-1 cells is demonstrated.
authors.affiliation: National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, 13164, Iran.
authors.forename: Shima
authors.initials: S
authors.lastname: Moradi-Kalbolandi
authors.affiliation: National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, 13164, Iran. Electronic address: habibi_m@pasteur.ac.ir.
authors.forename: Mahdi
authors.initials: M
authors.lastname: Habibi-Anbouhi
authors.affiliation: Parasitology Department, Pasteur Institute of Iran, Tehran, 13164, Iran.
authors.forename: Majid
authors.initials: M
authors.lastname: Golkar
authors.affiliation: Biotechnology Research Center, Venom & Biotherapeutics Molecules Lab, Pasteur Institute of Iran, Tehran, 13164, Iran.
authors.forename: Mahdi
authors.initials: M
authors.lastname: Behdani
authors.affiliation: National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, 13164, Iran.
authors.forename: Gashin
authors.initials: G
authors.lastname: Rezaei
authors.affiliation: National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, 13164, Iran.
authors.forename: Leila
authors.initials: L
authors.lastname: Ghazizadeh
authors.affiliation: Immunology Department, Hybridoma Lab, Pasteur Institute of Iran, Tehran, 13164, Iran. Electronic address: mabolhassani@yahoo.com.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Abolhassani
authors.affiliation: National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, 13164, Iran. Electronic address: mashokrgozar@pasteur.ac.ir.
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Shokrgozar
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D002460:Cell Line; D006801:Humans; D007377:Interleukin-3 / Q000276:immunology; D053650:Interleukin-3 Receptor alpha Subunit / Q000037:antagonists & inhibitors* / Q000276:immunology; D051379:Mice; D057127:Single-Chain Antibodies / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology / Q000494:pharmacology
chemical_list: D018033:Antibodies, Bispecific; C508596:IL3 protein, human; C115022:IL3RA protein, human; D007377:Interleukin-3; D053650:Interleukin-3 Receptor alpha Subunit; D057127:Single-Chain Antibodies
keywords: AML; Antibody engineering; Bivalent scFv (biscFv); CD123; Leukemic cancer stem cells